Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1983 1
1988 1
1989 4
1992 3
1993 3
1994 281
1995 844
1996 982
1997 1256
1998 1388
1999 1250
2000 1597
2001 1600
2002 1742
2003 1843
2004 2036
2005 2214
2006 2468
2007 2648
2008 3013
2009 3044
2010 3759
2011 4646
2012 5268
2013 5669
2014 6349
2015 6996
2016 7055
2017 7195
2018 5326
2019 2299
2020 88
Text availability
Article attribute
Article type
Publication date

Search Results

72,304 results
Results by year
Filters applied: . Clear all
Page 1
[Graft-versus-host disease-free, and relapse-free survival in Japanese patients with hematological malignancies].
Inamoto Y. Rinsho Ketsueki 2018 - Review. PMID 30185712 Japanese.
Graft-versus-host disease (GVHD) -free, relapse-free survival (GRFS) is an important, composite endpoint for clinical trials, which provides a patient-centered measure of transplant success. ...Other factors associated with increased GRFS rates included female patients; use of anti-thymocyte globulin prophylaxis for standard-risk disease; recent transplantations; gender combinations other than from a female donor to a male patient; absence of prior autologous transplantation; myeloablative conditioning; negative cytomegalovirus serostatus; and use of tacrolimus-based GVHD prophylaxis. ...
Graft-versus-host disease (GVHD) -free, relapse-free survival (GRFS) is an important, composite endpoint for cli …
Is there a standard of care for relapsed AML?
Medeiros BC. Best Pract Res Clin Haematol 2018 - Review. PMID 30466752
Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. The median overall survival for patients with relapsed AML ranges from 4-6 months and long-term survival from the time of relapse ranges from 5%-20%. ...
Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. T …
[Evaluation of disease free survival after radical resection for primary duodenal adenocarcinoma].
Jiang QL, et al. Zhonghua Yi Xue Za Zhi 2016. PMID 27866532 Chinese.
Objective: To investigate the risk factors associated with the disease free survival (DFS) for primary duodenal adenocarcinoma patients undergoing radical resection. ...The median disease free survival time was 26 months and the postoperative 1, 3, 5 year DFS rate were 79.7%, 60.3% and 53.6%, respectively. ...
Objective: To investigate the risk factors associated with the disease free survival (DFS) for primary duodenal adenoca …
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle C, et al. Ann Oncol 2016 - Review. PMID 27681864 Free PMC article.
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented. ...Studies were assessed for design and quality, and a meta-analysis was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS), to inform future trial design. ...
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.
Robinson AG, et al. Eur J Cancer 2014 - Review. PMID 24930623
Disease-free survival (DFS) is an end-point for an increasing number of clinical trials in adjuvant and curative intent cancer treatment informing both regulatory bodies and clinical practice. ...
Disease-free survival (DFS) is an end-point for an increasing number of clinical trials in adjuvant and curative intent
72,304 results
Jump to page
Feedback